Kisspeptin (Kisspeptin-10 / Kisspeptin-54)
Kisspeptin is a neuropeptide encoded by the KISS1 gene that is the master upstream regulator of the reproductive hormone cascade. It stimulates GnRH (gonadotropin-releasing hormone) neurons in the hypothalamus, which in turn triggers the release of LH and FSH from the pituitary gland. Kisspeptin is being actively researched in reproductive endocrinology for applications in fertility treatment, hormone assessment, and as a potential alternative to hCG in IVF protocols.
FormBlends Peptide Context
Reviewed May 14, 2026For Kisspeptin peptide guide, the useful question is what a reader can verify after leaving the page. The topic touches peptide therapy, so the content should help separate general education from anything that needs individualized clinician review.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
Kisspeptin authority snapshot
Kisspeptin is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Meaningful evidence with limits
Regulatory reality
Not specifically addressed in 2023/2026 regulatory actions
Safety screen
Flushing, Mild abdominal discomfort, Headache should be reviewed in context.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for Kisspeptin?
Kisspeptin should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- Kisspeptin
- Category
- Hormonal
- Evidence
- Meaningful evidence with limits
- FDA status
- Not FDA approved
Step 1
Check evidence level
Kisspeptin has been extensively studied in reproductive endocrinology. Multiple human trials confirm it stimulates LH and FSH release. A 2014 study in the Journal of Clinical Investigation showed kisspeptin-54 administration restored pulsatile GnRH secretion in women with hypothalamic amenorrhea. It's well-understood mechanistically with solid human pharmacological data.
Review evidenceStep 2
Screen safety context
Flushing, Mild abdominal discomfort, Headache should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessLast updated: April 3, 2026
Typical Dosage
Kisspeptin-10: 0.1-1 mcg/kg intravenously (research setting). Clinical protocols vary widely as dosing is still being established in ongoing trials.
Administration
Intravenous injection (research), Subcutaneous injection (clinical trials)
Typical Cost
$200-500/month (limited availability, primarily through research or specialized clinics)
FDA Status
Not FDA Approved
Half-Life
Kisspeptin-10: approximately 4 minutes. Kisspeptin-54: approximately 28 minutes.
Onset of Action
LH pulse occurs within 15-30 minutes of injection.
Bioavailability
Intravenous or subcutaneous injection. Very short-acting, especially the kisspeptin-10 form.
About Kisspeptin
Kisspeptin refers to a family of peptides encoded by the KISS1 gene. The most studied forms are kisspeptin-54 (the full-length active peptide) and kisspeptin-10 (the C-terminal decapeptide that retains full receptor binding activity). Kisspeptin-10 has a molecular weight of 1,302 Da.
Kisspeptin's role in human biology is to control the reproductive axis. It acts on GnRH (gonadotropin-releasing hormone) neurons in the hypothalamus through the KISS1R receptor (also called GPR54). When kisspeptin binds to these neurons, they release GnRH, which triggers the pituitary to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone). This cascade is the master switch for reproductive function in both men and women.
The discovery of kisspeptin's role came from studying patients with mutations in the KISS1R gene. These individuals fail to go through puberty and remain infertile, demonstrating that kisspeptin signaling is essential for reproductive function.
The most exciting clinical application is in IVF (in vitro fertilization). A 2014 study in the Journal of Clinical Investigation (PMID: 25365222) showed that kisspeptin-54 could trigger egg maturation in IVF patients as an alternative to hCG. The advantage: kisspeptin produced significantly lower rates of ovarian hyperstimulation syndrome (OHSS), a potentially dangerous complication of IVF. This research was led by Dr. Waljit Dhillo at Imperial College London.
In men, a 2011 study in the Journal of Clinical Endocrinology and Metabolism (PMID: 21470991) showed that kisspeptin-10 infusion acutely stimulated LH, FSH, and testosterone secretion in a dose-dependent manner. This has led to interest in using kisspeptin as a natural testosterone stimulant that works through the body's own signaling pathways rather than introducing exogenous testosterone.
The short half-life (4 minutes for kisspeptin-10, 28 minutes for kisspeptin-54) limits its practical use as a daily therapeutic. Most clinical research uses either continuous infusion or kisspeptin-54 for its longer duration.
Store lyophilized kisspeptin at -20C. Reconstitute with bacteriostatic water. Due to its very short half-life, reconstituted kisspeptin should be used promptly.
How Kisspeptin Works
Kisspeptin binds to the GPR54 receptor (also called KISS1R) on GnRH neurons in the hypothalamus. This binding triggers GnRH secretion, which stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The kisspeptin-GnRH-gonadotropin axis is the fundamental switch that controls puberty onset, fertility, and reproductive hormone production. Kisspeptin-10 (the 10-amino-acid form) and kisspeptin-54 (the full-length form) both activate GPR54 but differ in half-life and potency.
Receptor targets:
Benefits
- Stimulates natural testosterone production via the HPG axis
- Potential fertility treatment for both men and women
- May serve as a diagnostic tool for reproductive hormone disorders
- Being studied as a safer alternative to hCG for oocyte maturation in IVF
- Does not cause ovarian hyperstimulation syndrome risk seen with hCG
- Supports natural hormone production without suppressing feedback loops
What Does the Research Say?
Kisspeptin has been extensively studied in reproductive endocrinology. Multiple human trials confirm it stimulates LH and FSH release. A 2014 study in the Journal of Clinical Investigation showed kisspeptin-54 administration restored pulsatile GnRH secretion in women with hypothalamic amenorrhea. It's well-understood mechanistically with solid human pharmacological data.
PubMed evidence trail
Research sources used to frame this page
For Kisspeptin, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Potential Side Effects
- Flushing
- Mild abdominal discomfort
- Headache
- Transient changes in blood pressure
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| GnRH agonists/antagonists (leuprolide, cetrorelix) | Kisspeptin stimulates GnRH release upstream. GnRH analogs act downstream. Combining could produce unpredictable gonadotropin responses. | major |
Who Is Kisspeptin For?
Women
Active research area for IVF trigger, hypothalamic amenorrhea, and PCOS. The IVF application is particularly promising because kisspeptin has a lower risk of ovarian hyperstimulation syndrome than traditional hCG triggers.
Adults Over 50
Limited relevance in postmenopausal women as the reproductive axis is already downregulated. In men over 50, it may help stimulate endogenous testosterone production.
Athletes
Not specifically banned by WADA but could be considered under the peptide hormones category. Not typically used for performance enhancement.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Not specifically addressed in 2023/2026 regulatory actions
Kisspeptin is available through compounding pharmacies. It was not specifically restricted in the 2023 FDA actions.
Last verified: 2026-04-06
Conditions Addressed
Get Kisspeptin from FormBlends
Pharmaceutical-grade kisspeptin with free physician consultation.
View Product DetailsFind a Kisspeptin Clinic Near You
Browse peptide therapy clinics in your area that offer kisspeptin treatments.
Find Peptide Clinics